SMi’s 9th annual conference on Imaging in Cancer Drug Development will bring together key opinion leaders in the field of oncology and imaging to provide attendees with a comprehensive look into current advances in oncology imaging. This an unique opportunity to witness presentations on the current developments surrounding: oncology and diagnostic imaging modalities, drug development and clinical development alongside networking with key industry professionals.
To be held at The Copthorne Tara Hotel, London Kensington, this event will provide attendees with a complete view of the field and will focus primarily on oncology imaging modalities and applications in pre-clinical case studies, clinical imaging applications and innovations in imaging technology.
Benefits of attending the event
This year’s agenda offers an opportunity for debate and resolution of key challenges currently facing the field. This will encourage attendees to discuss growth in the field and exchange ideas, therefore driving the field forward and ensuring sufficient treatment of the key issues surrounding oncology imaging and drug development. Moreover, the event serves as a platfrom for networking with key industry professionals and experts in cancer drug development from academia. Some of the scientific presentations which will be presented at the event include:
- Latest non-invasive imaging modalities for translational research
- Future aspects of oncology imaging including Cerenkov and hybrid systems
- Current role of PET, SPECT and CT in cancer imaging alongside overcoming challenges faced
- Novel target identification with biomarkers in diagnostic imaging
- Latest developments in oncology drug discovery including HTS of kinase inhibitors
- Practical tools for business expansion in the current economic climate
Speakers at the Event
- Bert Windhorst, Head, Radiopharmaceutical Chemistry, VU University Medical Centre
- Francois Lassailly, In-vivo Imaging Specialist, Cancer Research UK
- Peter Eggleton, Medical Director, Merck
- Prash Krishna, Director – Oncology, Clinical Development, Eisai
- l Werner Scheuer, Research Leader Preclinical Imaging; Pharma Research and Early Development, Roche Diagnostics
Who should attend
This event is unmissable for Chief Executives, Chief Scientific Officers, Presidents, Senior Vice Presidents, Vice Presidents, Heads, Senior Directors, Directors, Clinicians, Principal Scientists, Research Fellows, Principal Investigators, Managers, Project/Team Leaders in Imaging and Translational Medicine, Molecular Imaging, Cancer Research, Pre-clinical and clinical Imaging, PET Research, Medical Imaging and many more faculties.
- Advertisement -
